Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 8.35
+0.21 (2.58%)
Aug 20, 2026, 4:09 PM HKT
Alphamab Oncology Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,082 | 9,492 | 3,368 | 6,407 | 10,149 | 12,743 | |
Market Cap Growth | -11.66% | 181.81% | -47.42% | -36.88% | -20.36% | -16.28% |
Enterprise Value | 6,716 | 7,989 | 2,154 | 5,004 | 8,763 | 10,814 |
Last Close Price | 8.35 | 9.80 | 3.50 | 6.64 | 10.80 | 13.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 19.03 | - | - | - |
PS Ratio | 12.83 | 15.06 | 4.95 | 26.58 | 53.81 | 71.10 |
PB Ratio | 4.25 | 4.99 | 1.73 | 3.48 | 5.76 | 5.55 |
P/TBV Ratio | 4.25 | 4.99 | 1.73 | 3.48 | 5.76 | 5.55 |
P/FCF Ratio | - | - | 16.61 | - | - | - |
P/OCF Ratio | - | - | 14.91 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 10.66 | 12.68 | 3.16 | 20.76 | 46.46 | 60.34 |
EV/EBITDA Ratio | - | - | 12.24 | - | - | - |
EV/EBIT Ratio | - | - | 20.04 | - | - | - |
EV/FCF Ratio | - | - | 10.62 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.10 | 0.15 | 0.22 | 0.34 |
Debt / EBITDA Ratio | - | - | 1.04 | - | - | - |
Debt / FCF Ratio | - | - | 0.98 | - | - | - |
Net Debt / Equity Ratio | -0.72 | -0.72 | -0.76 | -0.69 | -0.64 | -0.72 |
Net Debt / EBITDA Ratio | 13.41 | 13.41 | -8.38 | 4.30 | 2.57 | 3.48 |
Net Debt / FCF Ratio | 8.00 | 8.00 | -7.27 | 4.81 | 2.34 | 2.82 |
Asset Turnover | 0.26 | 0.26 | 0.29 | 0.10 | 0.07 | 0.06 |
Inventory Turnover | 0.67 | 0.67 | 0.75 | 0.77 | 0.72 | 0.06 |
Quick Ratio | 5.29 | 5.29 | 6.41 | 5.55 | 3.72 | 3.22 |
Current Ratio | 5.68 | 5.68 | 6.74 | 5.84 | 3.88 | 3.32 |
Return on Equity (ROE) | -6.43% | -6.43% | 9.49% | -13.04% | -19.00% | -19.91% |
Return on Assets (ROA) | -4.42% | -4.42% | 2.88% | -9.50% | -11.21% | -9.72% |
Return on Capital Employed (ROCE) | -8.40% | -8.40% | 5.10% | -17.30% | -25.00% | -20.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.57% | -1.34% | 5.25% | -3.62% | -3.63% | -3.97% |
FCF Yield | -2.11% | -1.80% | 6.02% | -4.11% | -4.79% | -4.61% |
Buyback Yield / Dilution | 2.31% | 2.31% | -2.53% | -2.50% | -0.11% | -0.62% |